SPOTLIGHT -
EP. 1: Classification of Triple Negative Breast Cancer
EP. 2: Histologic Subtyping in TNBC
EP. 3: Germline BRCA Mutations in TNBC
EP. 4: NCCN Guideline Changes for BRCA Testing in TNBC
EP. 5: Sequencing in BRCA-Positive TNBC Patients
EP. 6: Combining PARP Inhibitors + Checkpoint Inhibitors in TNBC
EP. 7: Neoadjuvant Therapy in TNBC
EP. 8: Anthracycline-Based Regimens: Perioperative Setting for TNBC
EP. 9: No pCR in Patients After Neoadjuvant Chemotherapy in TNBC
EP. 10: Paclitaxel vs Nab-Paclitaxel in Metastatic TNBC
EP. 11: Antibody-Drug Conjugates in Treating TNBC
EP. 12: Checkpoint Inhibitor Monotherapy for TNBC
EP. 13: Combination Therapy for TNBC: Checkpoint Inhibitor + Chemotherapy
EP. 14: Role of the Androgen Receptor in TNBC
EP. 15: Other Promising Targets in TNBC
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
